These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 2807550)
21. Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans. Wahid R; Pasetti MF; Maciel M; Simon JK; Tacket CO; Levine MM; Sztein MB Clin Immunol; 2011 Feb; 138(2):187-200. PubMed ID: 21146460 [TBL] [Abstract][Full Text] [Related]
22. [Stable expression and immunogenicity in a attenuated Salmonella typhi strain of coli surface antigen-6 of enterotoxigenic Escherichia coli]. Teng J; Rui X; Zhang Y; Zhang Z; Su G Wei Sheng Wu Xue Bao; 1999 Dec; 39(6):533-8. PubMed ID: 12555559 [TBL] [Abstract][Full Text] [Related]
23. Cloning, expression and characterization of heat shock protein 60 (groEL) of Salmonella enterica serovar Typhi and its role in protective immunity against lethal Salmonella infection in mice. Paliwal PK; Bansal A; Sagi SS; Mustoori S; Govindaswamy I Clin Immunol; 2008 Jan; 126(1):89-96. PubMed ID: 18024219 [TBL] [Abstract][Full Text] [Related]
24. Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a typhoid vaccine strain. Formal SB; Baron LS; Kopecko DJ; Washington O; Powell C; Life CA Infect Immun; 1981 Dec; 34(3):746-50. PubMed ID: 6174449 [TBL] [Abstract][Full Text] [Related]
25. Cross-reactive immune response elicited by parenteral Vi polysaccharide typhoid vaccine against non-typhoid Salmonellae. Pakkanen SH; Kantele JM; Herzog C; Kantele A Vaccine; 2014 Jan; 32(5):544-51. PubMed ID: 24342246 [TBL] [Abstract][Full Text] [Related]
26. Lack of immune response to the Vi component of a Vi-positive variant of the Salmonella typhi live oral vaccine strain Ty21a in human studies. Tacket CO; Losonsky G; Taylor DN; Baron LS; Kopecko D; Cryz S; Levine MM J Infect Dis; 1991 Apr; 163(4):901-4. PubMed ID: 2010645 [TBL] [Abstract][Full Text] [Related]
27. Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated DeltaguaBA Salmonella enterica serovar Typhi strain CVD 915. Wang JY; Pasetti MF; Noriega FR; Anderson RJ; Wasserman SS; Galen JE; Sztein MB; Levine MM Infect Immun; 2001 Aug; 69(8):4734-41. PubMed ID: 11447145 [TBL] [Abstract][Full Text] [Related]
28. A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans. Hone DM; Attridge SR; Forrest B; Morona R; Daniels D; LaBrooy JT; Bartholomeusz RC; Shearman DJ; Hackett J Infect Immun; 1988 May; 56(5):1326-33. PubMed ID: 3356467 [TBL] [Abstract][Full Text] [Related]
29. Live oral typhoid vaccine Salmonella Typhi Ty21a - a surrogate vaccine against non-typhoid salmonella? Kantele A; Pakkanen SH; Siitonen A; Karttunen R; Kantele JM Vaccine; 2012 Nov; 30(50):7238-45. PubMed ID: 23084770 [TBL] [Abstract][Full Text] [Related]
30. Significance of Vi Negative Isolates of Salmonella Enterica Serovar Typhi. Haque A Adv Exp Med Biol; 2018; 1052():9-18. PubMed ID: 29785477 [TBL] [Abstract][Full Text] [Related]
31. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. Robbins JD; Robbins JB J Infect Dis; 1984 Sep; 150(3):436-49. PubMed ID: 6207249 [TBL] [Abstract][Full Text] [Related]
32. Characterization and immunogenicity of EX880, a Salmonella typhi Ty21a-based clone which produces Vibrio cholerae O antigen. Attridge SR; Dearlove C; Beyer L; van den Bosch L; Howles A; Hackett J; Morona R; LaBrooy J; Rowley D Infect Immun; 1991 Jul; 59(7):2279-84. PubMed ID: 1711014 [TBL] [Abstract][Full Text] [Related]
33. Differential Killing of Salmonella enterica Serovar Typhi by Antibodies Targeting Vi and Lipopolysaccharide O:9 Antigen. Hart PJ; O'Shaughnessy CM; Siggins MK; Bobat S; Kingsley RA; Goulding DA; Crump JA; Reyburn H; Micoli F; Dougan G; Cunningham AF; MacLennan CA PLoS One; 2016; 11(1):e0145945. PubMed ID: 26741681 [TBL] [Abstract][Full Text] [Related]
34. In vivo evidence of immunological masking of the Vibrio cholerae O antigen of a hybrid Salmonella typhi Ty21a-Vibrio cholerae oral vaccine in humans. Forrest BD; LaBrooy JT Vaccine; 1991 Jul; 9(7):515-20. PubMed ID: 1716810 [TBL] [Abstract][Full Text] [Related]
35. Protective efficacy and immunogenicity of Vi-porin conjugate against Salmonella typhi. Singh M; Ganguly NK; Kumar L; Vohra H Microbiol Immunol; 1999; 43(6):535-42. PubMed ID: 10480549 [TBL] [Abstract][Full Text] [Related]
37. Efficacy of purified Vi polysaccharide typhoid vaccine. Park JH; Hong JJ; Choi ES; Lee JW; Park JH J Vet Sci; 2002 Jun; 3(2):67-70. PubMed ID: 12441674 [TBL] [Abstract][Full Text] [Related]
38. Development of a DNA probe to detect Salmonella typhi. Rubin FA; Kopecko DJ; Noon KF; Baron LS J Clin Microbiol; 1985 Oct; 22(4):600-5. PubMed ID: 3001134 [TBL] [Abstract][Full Text] [Related]
39. Use of the alpha-hemolysin secretion system of Escherichia coli for antigen delivery in the Salmonella typhi Ty21a vaccine strain. Gentschev I; Dietrich G; Spreng S; Neuhaus B; Maier E; Benz R; Goebel W; Fensterle J; Rapp UR Int J Med Microbiol; 2004 Oct; 294(6):363-71. PubMed ID: 15595386 [TBL] [Abstract][Full Text] [Related]
40. Characterization of defined ompR mutants of Salmonella typhi: ompR is involved in the regulation of Vi polysaccharide expression. Pickard D; Li J; Roberts M; Maskell D; Hone D; Levine M; Dougan G; Chatfield S Infect Immun; 1994 Sep; 62(9):3984-93. PubMed ID: 8063417 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]